Trial
NCT02012959
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
Syneos Health
Condition
Hyponatremia
Intervention
Tolvaptan
Why stopped
Issues with participant recruitment \& enrollment which made the trial impossible or highly impracticable. Trial termination was not due to safety reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-09-26